Supreme Court Directs Formation of Committee on Pharma Freebies
The Supreme Court mandates a committee to investigate pharmaceutical companies offering incentives to doctors for drug prescriptions.
The Supreme Court has ordered the formation of a committee to address the issue of pharmaceutical companies providing freebies to doctors.
The committee will review suggestions from stakeholders and report back to the Central government by January 29.
A public interest litigation highlights the need for legal backing to regulate unethical marketing practices in the pharmaceutical sector.
In a significant ruling on Thursday, the Supreme Court of India instructed the Central government to establish a committee aimed at investigating the practice of pharmaceutical companies offering incentives, such as freebies, to doctors to encourage them to prescribe their medications. This directive came during the hearing of a public interest litigation (PIL) filed by the Federation of Medical & Sales Representatives Association of India against the Union of India.
The bench, comprising Justices Vikram Nath and Sandeep Mehta, emphasized the importance of examining the suggestions and representations from various stakeholders involved in the healthcare sector. The court has scheduled a follow-up hearing on January 29 to review the compliance affidavit from the Union government regarding the formation of this committee.
The PIL, represented by advocate Aparna Bhat, argued that the right to health is an integral part of the right to life, necessitating that pharmaceutical companies adhere to ethical marketing practices. Currently, there is no legal framework that prohibits the provision of freebies to doctors, as the Uniform Code of Pharmaceutical Marketing Practices (UCPMP) lacks statutory backing. The petitioners highlighted that the absence of regulation allows for rampant corruption in pharmaceutical marketing, despite India being a signatory to the UN Convention against corruption.
The implications of these unethical practices are profound, as patients often end up paying exorbitant prices for medications that are over-prescribed or irrationally recommended by doctors in exchange for gifts and other incentives. The petitioners expressed concern that such practices not only jeopardize patient health but also shield pharmaceutical companies from accountability, while doctors face penalties for misconduct.
In light of these issues, the petitioners have urged the government to provide a statutory basis for the UCPMP, ensuring effective monitoring, transparency, and accountability. They have also requested that the Supreme Court consider issuing guidelines to make the UCPMP binding, thereby enhancing ethical standards in pharmaceutical marketing practices.
